Tatsuno Ichiro
Center for Diabetes, Metabolism and Endocrinology, Toho University Sakura Medical Center, 564-1 Shimoshizu, Sakura, Chiba 285-8741, Japan.
Expert Rev Cardiovasc Ther. 2014 Nov;12(11):1261-8. doi: 10.1586/14779072.2014.971756. Epub 2014 Oct 16.
A number of epidemiological/observational studies, as well as large-scale randomized intervention studies, have been conducted to provide evidence for the efficacy of ω-3 fatty acids against atherosclerotic diseases. Currently, ω-3 fatty acids are commercially available in many parts of the world containing the same active ingredients as Lotriga(®) (ω-3-acid ethyl esters 90 [O3AE highly concentrated ω-3 fatty acid ethyl esters, consisting of eicosapentaenoic acid-ethyl ester and docosahexaenoic acid-ethyl ester [EPA-E/DHA-E]). A recent head-to-head comparative study of O3AEE90 versus EPA-E demonstrated that O3AEE90 4g/day led to a significantly greater reduction in triglycerides (TG) than EPA-E 1.8g/day and that O3AEE90 2g/day produced comparable effects on TG to those with EPA-E 1.8g/day. While both agents were shown to be useful in lowering TG, the hallmark feature of O3AEE90, that is, the presence of the DHA-E component versus its absence in EPA-E, needs to be further examined for its clinical implications.
已经开展了多项流行病学/观察性研究以及大规模随机干预研究，以提供ω-3脂肪酸抗动脉粥样硬化疾病疗效的证据。目前，ω-3脂肪酸在世界许多地方都有商业销售，其活性成分与乐特瑞加（Lotriga®）相同（ω-3酸乙酯90 [O3AE，高浓缩ω-3脂肪酸乙酯，由二十碳五烯酸乙酯和二十二碳六烯酸乙酯（EPA-E/DHA-E）组成]）。最近一项O3AEE90与EPA-E的直接对比研究表明，每日服用4克O3AEE90比每日服用1.8克EPA-E能更显著地降低甘油三酯（TG），并且每日服用2克O3AEE90对TG产生的效果与每日服用1.8克EPA-E相当。虽然两种药物都显示出对降低TG有用，但O3AEE90的标志性特征，即其含有DHA-E成分而EPA-E中没有，其临床意义仍需进一步研究。
